A Comparative Study of Once versus Twice Daily Treatment of Superficial Dermatophyte and Yeast Infections with Tioconazole (1%) Cream

Publisher Website
Google Scholar
Abstract
Two open, multicentre studies were performed to evaluate the efficacy of 1% tioconazole cream (Trosyd®, Pfizer) as a once daily treatment for patients with common superficial dermatophyte and yeast infections (t. Pedis, t. versicolor, t. corporis, t. cruris, candidiasis). In Study I, forty-eight patients were treated once daily and forty-nine were treated twice daily. The clinical response rate at the last treatment visit was 96% and 98%, respectively, in the two treatment groups. In Study II, all 107 patients were treated once daily, and the clinical response rate was 95% at the last treatment visit. The mycological cure rates were 85% and 91% in the Study I groups, and 94% in Study II. At the long-term follow-up evaluation (approximately 4 weeks after treatment) favourable clinical responses were seen in 88% of patients in both the Study I groups, and in 94% of patients in Study II. Long-term mycological cures were seen in 80% of patients in both groups of Study I, and in 94% of patients in Study II. Side effects of treatment were generally transient, mild and coincident with disease symptoms, and occurred in six patients (6%) in Study I and in four patients (4%) in Study II. The results of both studies have shown no clinically or statistically significant differences in toleration or efficacy between once daily and twice daily treatment regimens with 1% tioconazole cream for the treatment of superficial dermatophyte infections.